Framing Messages for Smoking Cessation With Bupropion - 6

Not Applicable

Completed

• Conditions: Tobacco Use Disorder
• Interventions: Drug: Bupropion; Behavioral: Smoking Abstinence Program

• Registration Number: NCT00104598
• Lead Sponsor: Yale University

Brief Summary

This is a randomized study of message framing in individuals beginning a smoking cessation program utilizing bupropion SR and brief counseling, videos, and pamphlets.

Detailed Description

Not available

Study Timeline

• Study Start: 2000-09
• Primary Completion: 2004-09
• Study First Submitted: 2005-03-01
• Study First Submitted QC: 2005-03-01
• Study First Posted: 2005-03-02
• Study Completion: 2006-12
• Status Verified: 2013-08
• Last Update Submitted: 2013-08-07
• Last Update Posted: 2013-08-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 252

Inclusion Criteria

Not provided

Exclusion Criteria

• Pregnant or nursing women, or women of child-bearing potential who are not using an adequate method of contraception
• Psychiatric illnesses requiring psychotropic medications (i.e., psychosis, major depression, mania), or the presence of suicidality or homocidality
• Current use of nicotine replacement therapies (i.e., nicotine patch, gum, or lozenges, nasal spray, or inhaler), bupropion (Zyban, Wellbutrin), or marijuana or current participation in another smoking cessation treatment
• Presence of unstable medical conditions (i.e., cardiac, hepatic, renal disease, diabetes mellitus) that would make a trial of bupropion SR hazardous
• Have taken monoamine oxidase inhibitors or metoprolol succinate within the past six weeks
• History of anorexia nervosa or bulimia
• Previous hypersensitivity to bupropion
• History of alcohol or other drug dependence in the past one year
• History of seizure disorder of any etiology (i.e., brain tumor, traumatic brain injury, substance-induced seizures, etc.)
• Any finding that in the view of the principal investigator would compromise the subject's ability to fulfill the protocol visit schedule and visit requirements or put the subject at risk
• Sharing home or work environment with current or past participant
• No couples or participants who see each other every day

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Gain Framed Absitnence Program	Smoking Abstinence Program	Gain framed video and printed messages encouraging smoking abstinence with Bupropion.
Loss Framed Abstinence Program	Smoking Abstinence Program	Loss framed video and printed messages encouraging smoking abstinence with Bupropion.
Gain Framed Absitnence Program	Bupropion	Gain framed video and printed messages encouraging smoking abstinence with Bupropion.
Loss Framed Abstinence Program	Bupropion	Loss framed video and printed messages encouraging smoking abstinence with Bupropion.

Primary Outcome Measures

Name	Time	Method
Smoking Cessation at 7 days	7-day point prevalence abstinence
Continuous Smoking Abstinence at 6 weeks	6 weeks	6-week continuous abstinence.

Trial Locations

Locations (1)

Substance Abuse Treatment Unit; 🇺🇸 New Haven, Connecticut, United States